FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:2460-2461 December 18, 2003 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Martínez, E. PubMed Citation

To the Editor: Martínez et al. (Sept. 11 issue)¹ report that among patients who switched to efavirenz from a protease inhibitor, 29 (18.6 percent) subsequently discontinued efavirenz without virologic failure. This proportion is considerably in excess of that reported by Staszewski et al. in the pivotal study that established the superior efficacy of efavirenz in comparison with indinavir (4 percent).²

My colleagues and I have found that switching to efavirenz from a protease inhibitor is less well tolerated by patients who have acquired human immunodeficiency virus (HIV) infection through intravenous drug use than by other patients, with a 25 percent . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.